Introduction
Mevalonate kinase deficiency (MKD) is a rare hereditary autoinflammatory syndrome that can lead to significant morbidity. Evidence-based guidelines are lacking and management is mostly based on physician's experience. Consequently, treatment regimens differ throughout Europe. In 2012, a European initiative called SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) was launched to optimize and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases.
Objectives
One of the aims of SHARE was to provide evidence based recommendations for diagnosis and treatment of MKD.
Methods
Evidence based recommendations were developed using the European League Against Rheumatism (EULAR) standard operating procedure. An expert committee was instituted, consisting of pediatric and adult rheumatologists. The expert committee defined search terms for the systematic literature review. Two independent experts scored articles for validity and level of evidence. Recommendations derived from the literature were evaluated by an online survey. Those with less than 80% agreement on the online survey or with relevant comments of the experts were reformulated. Subsequently, all recommendations were discussed at a consensus meeting using the nominal group technique. Recommendations were accepted if more than 80% agreement was reached.
Results
The literature search yielded 618 articles, of which 28 were considered relevant and therefore scored for validity and level of evidence. Fourteen were scored valid and used in the formulation of the recommendations. Sixteen recommendations were suggested in the online survey and discussed during the consensus meeting. Six general recommendations on management, three recommendations for diagnosis, six for monitoring and seven for treatment were accepted with more than 80% agreement.. Topics covered are the use of the multidisciplinary team, treatment goals, and vaccinations [general recommendations], Gaslini diagnostic score, IgD and urinary mevalonic acid excretion [diagnosis]; the use of AIDAI in clinical studies, monitor frequency, minimal assessments in all MKD and additional assessments in severe MKD patients, infection and macrophage activation syndrome [monitoring], NSAIDs, glucocorticoids, IL-1 blockade, etanercept, switching biologicals, colchicine, statins and hematopoietic stem cell transplantation [treatment] .
Conclusion
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